There is probably no limit to what technology and its multifaceted science can do to change the course of human history. Scientific inventions, innovations and their major technological breakthrough serves as a reminder that the solution to the future of the human race are embedded in the laws of nature, whether on uncertainty principle or relative theory of understanding. There is considerable understanding that science shall come up with a body of everything, or what scientists call a theory of everything (TOE) and that it is still possible in the future. These views serve to inspire one Jason Hope who has narrowed this hope in science into an internet of everything that he believes can be realized in this near future.

Jason hope has dedicated his intellect into exploring his heartfelt believe that various devices can be synchronized with each other from the clothes we wear, to the car we drive to our kitchen devices using the same data therefore serving as an important source of information, work practice and diagnostic leveraging point. He particularly has as a shoe he uses while practicing that can measure the progress of exercising.

Jason Hope faith in this role of technology in the future of the human race can also be exemplified by his record breaking donation to biotechnology research institution (SENS). These donations are stemmed from his believe that aging and various others chronic diseases can be eliminated by putting more emphasis on what happens at the cellular level, a point that has been by scientifically proved by the use of stem cells, though still opposed by moral and ethical scholars. His donations are tenable noting success of stem cells cure in various conditions including HIV/AIDs. The impact of biotechnology in treating age related diseases has been appreciated however and it now points to the future, what it has in store for mankind. Jason hope is an alma mater of Arizona State University, where he graduated with an MBA. He chose to invest in mobile technology for he realized the opportunity it held in that its market was big, and unexploited.

Learn More: https://en.wikipedia.org/wiki/SENS_Research_Foundation

JHSF was founded in 1972 and it has four units with a total of up to five thousand employees. Its director president is AuriemoNeto and the vice president is Eduardo Camara. In 2001, it expanded its operations to the development of shopping centres. Today, it is the leading real estate company in Brazil and has participated in many residential and commercial incorporations in the country. They have built high end shopping centres and hotels and even constructed an international airport.

The company has received recognition for its outstanding ability to recognise and take advantage of rising opportunities in the Brazilian market. JHSF has branches in different cities that include New York, Sao Paulo, Miami, Manaus and Uruguay and all of them are performing well. Another outstanding attribute of JHSF is its innovation and development of sustainable solutions to the projects undertaken by the firm. JHSF was listed as one of the leading corporate governance segments.

José AuriemoNeto is the chairman and chief executive officer of JHSF. He went to the University of FundacaoAlvaresPenteado in San Paulo. José AuriemoNeto earned the right to do real estate business in 1993 and developed the first shopping centre by his company known as the shopping Santa Cruz in 1998. Santa Cruz was later sold to Brmalls in 2010 as JHSF shifted its focus to the high income market. This was a great step towards growth by the company. Click here to know more.

The real estate company focuses on residential and commercial development of properties in Brazil. AuriemoNeto oversees building of the company’s brand and is also responsible for administration of the company’s retail portfolio. In 2009, JHSF formed its first retail outlet under the leadership of Aureimo. The group formed partnership with other organizations that include Hermes, Jimmy Choo and Pucci to open its first retail luxury brands.

Jose Auriemo intensified the performance of the company and opened the company’s capital allowing it to offer its shares in the financial market of Brazil. JHSF acquired shares of GrupoFasano Hotels in 2007 and by the year 2014, it gained control of the group restaurant’s shareholders.

Seattle Genetics is Washington’s largest biotech company, and is slowly but surely moving to the big pharma league. It is valued at almost $10 billion, and has 900 employees and plans to increase the number to 1,100. The company was founded in 1998 by Clay Siegall, who is currently its CEO. It has done extensive research on oncology and cancer treatment, and has been studying human antibodies to find out how they can be used to fight cancer.

 

Seattle Genetics has 11 cancer drugs in the works, 4 of which are likely to be released into the market soon. These 4 are in the final stages of testing. One of these is Adcetris, which is being tested for use as a front-line drug in the treatment of Hodgkin lymphoma, a type of cancer which affects the lymphatic system. Adcetris has already been approved by the FDA for use by patients whose first or second drugs are not effective. Projected annual sales from it are $1 billion if it is approved as a front-line treatment. Seattle Genetics is also doing research on the possibility of using Adcetris in combination with Opdivo, a type of checkpoint inhibitor used in immunotherapy. The other 3 drugs are for the treatment of bladder cancer, breast cancer, and acute myeloid leukemia. The approval of these drugs will be a huge step in the treatment of these types of cancer.

 

About Clay Siegall

Clay Siegall has extensive experience in the biopharmaceutical industry and is very passionate about the fight against cancer. Under his leadership, Seattle Genetics has played a great role in advancements in the treatment against cancer. His secret to success is diversification. Unlike other biotech companies which focus all their energies on one or two drugs and end up crumbling if they are not approved, he does extensive research on different types of cancer and the existing treatment options. This enables him to produce more effective drugs. He also learns from industry authorities and tries to emulate some of their business models in Seattle Genetics. This is how Clay Siegall ensures that Seattle Genetics remains relevant in the industry.

 

Conclusion

Clay Siegall is committed to the fight against cancer, and this is what gives him the motivation to keep researching and producing cancer drugs. He acknowledges that it is not easy but nothing will stop him. Thanks to his visionary leadership, Seattle Genetics has made huge strides in the treatment of cancer and continues to forge on despite the numerous challenges in the industry.